These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 1564212)
1. Confronting the issues of patient safety and investigator conflict of interest in an international clinical trial of myocardial reperfusion. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) Steering Committee. Topol EJ; Armstrong P; Van de Werf F; Kleiman N; Lee K; Morris D; Simoons M; Barbash G; White H; Califf RM J Am Coll Cardiol; 1992 May; 19(6):1123-8. PubMed ID: 1564212 [TBL] [Abstract][Full Text] [Related]
2. Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. The GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. Holmes DR; Bates ER; Kleiman NS; Sadowski Z; Horgan JH; Morris DC; Califf RM; Berger PB; Topol EJ J Am Coll Cardiol; 1995 Sep; 26(3):668-74. PubMed ID: 7642857 [TBL] [Abstract][Full Text] [Related]
3. Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators. Simes RJ; Topol EJ; Holmes DR; White HD; Rutsch WR; Vahanian A; Simoons ML; Morris D; Betriu A; Califf RM Circulation; 1995 Apr; 91(7):1923-8. PubMed ID: 7895348 [TBL] [Abstract][Full Text] [Related]
4. Noninvasive assessment of speed and stability of infarct-related artery reperfusion: results of the GUSTO ST segment monitoring study. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. Langer A; Krucoff MW; Klootwijk P; Veldkamp R; Simoons ML; Granger C; Califf RM; Armstrong PW J Am Coll Cardiol; 1995 Jun; 25(7):1552-7. PubMed ID: 7759706 [TBL] [Abstract][Full Text] [Related]
5. Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries. Results from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. Van de Werf F; Topol EJ; Lee KL; Woodlief LH; Granger CB; Armstrong PW; Barbash GI; Hampton JR; Guerci A; Simes RJ JAMA; 1995 May 24-31; 273(20):1586-91. PubMed ID: 7745771 [TBL] [Abstract][Full Text] [Related]
6. Lessons we have learned from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries. Holmes DR; Califf RM; Topol EJ J Am Coll Cardiol; 1995 Jun; 25(7 Suppl):10S-17S. PubMed ID: 7775708 [TBL] [Abstract][Full Text] [Related]
7. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators. Weaver WD; White HD; Wilcox RG; Aylward PE; Morris D; Guerci A; Ohman EM; Barbash GI; Betriu A; Sadowski Z; Topol EJ; Califf RM JAMA; 1996 Mar; 275(10):777-82. PubMed ID: 8598594 [TBL] [Abstract][Full Text] [Related]
8. Early angiography cannot predict postthrombolytic coronary reocclusion: observations from the GUSTO angiographic study. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. Reiner JS; Lundergan CF; van den Brand M; Boland J; Thompson MA; Machecourt J; Py A; Pilcher GS; Fink CA; Burton JR J Am Coll Cardiol; 1994 Nov; 24(6):1439-44. PubMed ID: 7930273 [TBL] [Abstract][Full Text] [Related]
9. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. GUSTO investigators N Engl J Med; 1993 Sep; 329(10):673-82. PubMed ID: 8204123 [TBL] [Abstract][Full Text] [Related]
10. Is survival in acute myocardial infarction related to thrombolytic efficacy or the open-artery hypothesis? A controversy to be investigated with GUSTO. Bates ER Chest; 1992 Apr; 101(4 Suppl):140S-150S. PubMed ID: 1555479 [TBL] [Abstract][Full Text] [Related]
11. Differential effects of tissue plasminogen activator and streptokinase on infarct size and on rate of enzyme release: influence of early infarct related artery patency. The GUSTO Enzyme Substudy. Baardman T; Hermens WT; Lenderink T; Molhoek GP; Grollier G; Pfisterer M; Simoons ML Eur Heart J; 1996 Feb; 17(2):237-46. PubMed ID: 8732377 [TBL] [Abstract][Full Text] [Related]
12. Holding GUSTO up to the light. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. Lee KL; Califf RM; Simes J; Van de Werf F; Topol EJ Ann Intern Med; 1994 May; 120(10):876-81; discussion 882-5. PubMed ID: 8154647 [TBL] [Abstract][Full Text] [Related]
13. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. GUSTO Angiographic Investigators N Engl J Med; 1993 Nov; 329(22):1615-22. PubMed ID: 8232430 [TBL] [Abstract][Full Text] [Related]
14. One-year results from the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) trial. GUSTO-I Investigators. Califf RM; White HD; Van de Werf F; Sadowski Z; Armstrong PW; Vahanian A; Simoons ML; Simes RJ; Lee KL; Topol EJ Circulation; 1996 Sep; 94(6):1233-8. PubMed ID: 8822974 [TBL] [Abstract][Full Text] [Related]
15. New developments in thrombolytic therapy. Collen D; Gold HK Adv Exp Med Biol; 1990; 281():333-54. PubMed ID: 2129372 [TBL] [Abstract][Full Text] [Related]
16. Reperfusion therapy for acute myocardial infarction. Which strategy for which patient? Boersma E; Steyerberg EW; Van der Vlugt MJ; Simoons ML Drugs; 1998 Jul; 56(1):31-48. PubMed ID: 9664197 [TBL] [Abstract][Full Text] [Related]
17. The prognostic value of bleeding academic research consortium (BARC)-defined bleeding complications in ST-segment elevation myocardial infarction: a comparison with the TIMI (Thrombolysis In Myocardial Infarction), GUSTO (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries), and ISTH (International Society on Thrombosis and Haemostasis) bleeding classifications. Kikkert WJ; van Geloven N; van der Laan MH; Vis MM; Baan J; Koch KT; Peters RJ; de Winter RJ; Piek JJ; Tijssen JG; Henriques JP J Am Coll Cardiol; 2014 May; 63(18):1866-75. PubMed ID: 24657697 [TBL] [Abstract][Full Text] [Related]
18. Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-I trial. Global Utilization of Streptokinase and TPA for Occluded coronary arteries trial. White HD; Barbash GI; Califf RM; Simes RJ; Granger CB; Weaver WD; Kleiman NS; Aylward PE; Gore JM; Vahanian A; Lee KL; Ross AM; Topol EJ Circulation; 1996 Oct; 94(8):1826-33. PubMed ID: 8873656 [TBL] [Abstract][Full Text] [Related]
19. Clinical predictors of early infarct-related artery patency following thrombolytic therapy: importance of body weight, smoking history, infarct-related artery and choice of thrombolytic regimen: the GUSTO-I experience. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. Lundergan CF; Reiner JS; McCarthy WF; Coyne KS; Califf RM; Ross AM J Am Coll Cardiol; 1998 Sep; 32(3):641-7. PubMed ID: 9741505 [TBL] [Abstract][Full Text] [Related]
20. Mortality within 24 hours of thrombolysis for myocardial infarction. The importance of early reperfusion. The GUSTO Investigators, Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. Kleiman NS; White HD; Ohman EM; Ross AM; Woodlief LH; Califf RM; Holmes DR; Bates E; Pfisterer M; Vahanian A Circulation; 1994 Dec; 90(6):2658-65. PubMed ID: 7994805 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]